Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
9
×
boston blog main
boston top stories
biotech
clinical trials
roche
seattle blog main
seattle top stories
cancer
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
blueprint medicines
deals
investing
amgen
avapritinib
boston
cancer drugs
checkpoint inhibitors
drugs
What
cancer
9
×
drug
9
×
fda
medicine
medicines
approval
blueprint
genetic
marketing
ret
roundup
targets
tiny
adding
address
advanced
ahead
alzheimer's
ambien
american
annual
approved
approves
arrival
asco
attendees
attention
award
bad
bets
bio
biotech
boost
brain
camp’s
candidate
carries
case
cash
certain
Language
unset
Current search:
cancer
×
drug
×
" san francisco top stories "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More